A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis
Year: 2019
Type: conference-abstract
Source: Blood
Institutions: Jagiellonian University, Istituto di Ematologia di Bologna, University of Bologna, Johannes Gutenberg University Mainz, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Hospital Universitario Puerta de Hierro Majadahonda, Universidad Autónoma de Madrid, Semmelweis University, Medical University of Lodz, The Ohio State University Wexner Medical Center, The Ohio State University, Universität Ulm, MorphoSys (Germany), Emory University, Winship Cancer Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2986154089